World Vaccine Congress Washington, April 7-9 2015

Download eBook: Discussion topics from Pandemic Influenza, 2nd Edition

Pandemic influenza is a re-emerging disease with serious public health consequences. The H1N1 pandemic in 2009-10 and the continuing threat to humans from avian influenza H5N1 and H5N8 have underlined this threat. Particularly in an increasingly globalised society, it is essential that we have preparedness plans in please at a local, national and international level. Download this eBook to: Gain …

Retroscreen Virology Senior Medical Director to speak at World Vaccine Congress USA 2015

The world’s leading research company in human viral challenge models, Retroscreen Virology, has announced one of its scientific and medical leadership team will be speaking at 2015 World Vaccine Congress in the USA. Dr Martin Johnson, Senior Medical Director at Retroscreen Virology, is going to be talking about the Retroscreen hVIVO human viral challenge model and how it can be …

CDC: Early Data Suggests Potentially Severe Flu Season

December 5, 2014 Early data suggests that the current 2014-2015 flu season could be severe. The Centers for Disease Control and Prevention (CDC) urges immediate vaccination for anyone still unvaccinated this season and recommends prompt treatment with antiviral drugs for people at high risk of complications who develop flu. So far this year, seasonal influenza A H3N2 viruses have been …

World Vaccine Congress Brochure Available

  The World Vaccine Congress Washington is now in its 15th year, and things look a little different to previous years. ‘So why the change?’ I hear you ask… In my previous role, we produced very focused agendas and ran two-day events specifically on that area. This would be as niche as talking only about foundations for deep water offshore …

What Lies Ahead for The Vaccine Industry?

  We’ve got to ‘fight our corner’ was the message from Novartis’ David McIntosh as he opened up the 2014 World Vaccine Congress Europe You opened the conference this morning with the claim that ‘we need to fight our corner’ in the vaccine industry. Is the vaccine industry in trouble?   The pharmaceutical industry is broadly divided into pharma products …

Sarepta Therapeutics Announces Favorable Safety Results from Phase I Clinical Study of Influenza Drug Candidate

September 30, 2014 Sarepta Therapeutics, Inc., a developer of innovative RNA-based therapeutics, today announced favorable safety results from the single ascending dose portion of a Phase I study of AVI-7100, the company’s lead candidate for the treatment of influenza virus, in healthy volunteers. The clinical trial is being conducted at the National Institutes of Health (NIH) through a collaboration between …

bioCSL Inc. Launches AFLURIA Shipping Campaign for 2014-2015 Seasonal Influenza

August 5th, 2014 bioCSL Inc. to supply U.S. Market with 16.5 Million Doses Historical reliability, coupled with dedicated commercial and production efforts, drive strong customer prebook order demand Early season deliveries will support U.S. providers’ 2014-15 vaccination needs bioCSL Inc. announced today it has commenced shipping its seasonal influenza vaccine AFLURIA(Influenza Vaccine) for the 2014-2015 flu season. U.S. providers who ordered AFLURIA may …

The Animal Medicine and Veterinary Vaccines Sector – a $22 billion market

As highlighted by Zoetis , the largest global animal healthcare company and latest exhibitor partner to the Vaccine Congress Washington 2015, the animal medicines and veterinary vaccines sector is estimated to represent a global market of $22 billion within the approximate $92 – 102 billion animal health industry.   Additionally between 2011 and 2016, the animal medicines and vaccines sector is …

Vertex Licenses VX-787 to Janssen Pharmaceuticals for the Treatment of Influenza

VX-787 is an investigational medicine discovered by Vertex that is designed to directly inhibit replication of the influenza virus June 18, 2014 Vertex Pharmaceuticals Incorporated today announced that it has entered into a licensing agreement with Janssen Pharmaceuticals, Inc. for the worldwide development and commercialization of VX-787, a novel medicine discovered by Vertex for the treatment of influenza. As part …